Inovio Pharmaceuticals (NASDAQ:INO) Upgraded at StockNews.com

Inovio Pharmaceuticals (NASDAQ:INO) was upgraded by investment analysts at StockNews.com to a “sell” rating in a research note issued to investors on Friday.

A number of other equities research analysts also recently issued reports on INO. Royal Bank of Canada lowered their price objective on Inovio Pharmaceuticals from $6.00 to $5.00 and set a “sector perform” rating on the stock in a research report on Wednesday. JMP Securities restated a “market outperform” rating and set a $18.00 price target on shares of Inovio Pharmaceuticals in a research report on Friday, January 10th. Finally, HC Wainwright restated a “neutral” rating and set a $3.00 price target on shares of Inovio Pharmaceuticals in a research report on Wednesday. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $12.20.

Inovio Pharmaceuticals Stock Performance

NASDAQ INO traded down $0.02 on Friday, hitting $1.92. 2,019,265 shares of the stock traded hands, compared to its average volume of 551,698. The business’s fifty day moving average is $2.04 and its two-hundred day moving average is $3.71. Inovio Pharmaceuticals has a 12 month low of $1.74 and a 12 month high of $14.75. The firm has a market capitalization of $50.11 million, a price-to-earnings ratio of -0.91 and a beta of 0.92.

Inovio Pharmaceuticals (NASDAQ:INO) last announced its quarterly earnings data on Tuesday, March 18th. The biopharmaceutical company reported ($0.69) earnings per share for the quarter, beating the consensus estimate of ($0.87) by $0.18. The firm had revenue of $0.12 million for the quarter, compared to the consensus estimate of $0.03 million. Analysts expect that Inovio Pharmaceuticals will post -4.23 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. BNP Paribas Financial Markets increased its holdings in shares of Inovio Pharmaceuticals by 177.0% in the third quarter. BNP Paribas Financial Markets now owns 5,681 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 3,630 shares during the period. Barclays PLC grew its stake in shares of Inovio Pharmaceuticals by 15.0% in the fourth quarter. Barclays PLC now owns 39,114 shares of the biopharmaceutical company’s stock worth $71,000 after purchasing an additional 5,111 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Inovio Pharmaceuticals by 1.1% in the fourth quarter. Geode Capital Management LLC now owns 628,505 shares of the biopharmaceutical company’s stock worth $1,150,000 after purchasing an additional 6,874 shares during the last quarter. MetLife Investment Management LLC grew its stake in shares of Inovio Pharmaceuticals by 129.1% in the third quarter. MetLife Investment Management LLC now owns 15,167 shares of the biopharmaceutical company’s stock worth $88,000 after purchasing an additional 8,546 shares during the last quarter. Finally, Northern Trust Corp grew its stake in shares of Inovio Pharmaceuticals by 6.4% in the fourth quarter. Northern Trust Corp now owns 219,057 shares of the biopharmaceutical company’s stock worth $401,000 after purchasing an additional 13,269 shares during the last quarter. Hedge funds and other institutional investors own 26.79% of the company’s stock.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.